flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Effects of with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic disease in the Semaglutide reduced the risk of

WWLP reported that supporters of the coverage change "believe that removing these high-cost drugs from the coverage list will allow the agency to reduce expenses significantly as it struggles to pay claims." Roughly 25.3 percent of Massachusetts children ages six to 17 are overweight or obese

No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER Trial

OXM is a combination of glucagon and additional IP-1

The agency noted the prescribing information for GLP-1 drugs approved for weight loss includes warnings about the risk for suicidal thoughts and actions